Gain expert insight into treatment options for relapsed/refractory chronic lymphocytic leukemia (R/R CLL). View leading investigators discussing the standard of care for R/R CLL and how new trial data might impact the treatment paradigm.
Dec 21, 2017
Dec 21, 2018
Barbara Eichhorst, MD, PhDUniversity Hospital Cologne
John Gribben, MD, DSc, FRCP, FRCPath, FMedSciBarts Cancer Institute
London, United Kingdom
John Seymour, MBBS, PhD, FRACPPeter MacCallum Cancer Centre
Melbourne, Victoria, Australia
- Standard of care for relapsed/refractory CLL
- Combination therapy for CLL
- Second-generation targeted agents in CLL
This educational activity is intended for hematologists, oncologists, and other healthcare professionals involved in management of CLL.
Upon completion of this educational activity, participants should be able to:
- Identify features that can inform treatment decision making, such as persistence of minimal residual disease and the presence of deleterious cytogenetic aberrations
- Assess recent efficacy and safety results from investigations into novel treatment strategies for R/R CLL
- Select optimal treatment for patients with R/R CLL based on current best practices and recent trial data
This educational activity is supported by a grant from AbbVie.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.